Reckitt Benckiser’s feelings about Pfizer’s consumer unit haven’t changed since the company said in 2015 that it’d be keen to buy it. But its resources have.
The household goods company, in debt after its £13.2 billion buy of baby food maker Mead Johnson, will review all its financing options when Pfizer starts taking bidders on the unit, the U.K.’s Sunday Times reports.
Those could include a multibillion-pound rights issue, an asset swap or the purchase of individual assets from Pfizer’s portfolio, the newspaper’s sources say.
Pfizer officially confirmed earlier this month that it was weighing options for its OTC division, and the timing isn’t great for Reckitt. The company has slid since the Mead Johnson buy, suffering a sales slowdown, a cyberattack and four exec-committee exits. Plus, after its last big buy, the company could have trouble drumming up shareholder support for another big deal, Jefferies analysts have warned, pointing out in a note seen by The Times that a buy would take Reckitt’s net debt to more than four times its earnings.
RB, though, has had its eye on Pfizer’s OTC stable for quite some time; nearly two years ago, CEO Rakesh Kapoor told Bloomberg he’d be “very interested” in snapping it up. A deal between the two would bring well-known brands like Advil, ChapStick and Centrum to a Reckitt lineup that already includes Nurofen painkillers and Durex condoms.
“We think [Reckitt’s] best hope is that the Pfizer review plays long. This would give them the opportunity to sort out [Mead Johnson] and hopefully rebuild market confidence,” Jefferies’ analysts wrote.
If and when the auction comes around, though, Reckitt might find itself up against some hefty competition—though pharma’s consumer health enthusiasm seems to have cooled somewhat since the company pulled out of a two-horse race with Bayer over Merck’s OTC unit. Instead, it could wind up facing off against food behemoth Nestlé, which has said it’s scouting OTC drugs.
By Carly Helfand
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
